99(top 5%)
PR articles
5.1K(top 5%)
PR citations
34(top 5%)
PR h-index
38(top 5%)
h-index
131
documents
6.8K
doc citations
1.5K
citing journals
100
times ranked

Publications

100 peer-reviewed articles • 5,523 peer-reviewed citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1Inherited rare epidermal growth factor receptor mutation and somatic mutations in patients with non-small cell lung cancer: a case report
BMC Medical Genomics, 2025, 18,
1.71Citations (PDF)
2Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non–Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns
Clinical Cancer Research, 2024, 30, 4822-4833
6.89Citations (PDF)
3Spatial profiling of METex14-altered NSCLC under tepotinib treatment: Shifting the immunosuppressive landscape
Neoplasia, 2024, 57, 101063
7.01Citations (PDF)
4Overcoming MET-mediated resistance in oncogene-driven NSCLC
IScience, 2023, 26, 107006
3.610Citations (PDF)
5BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
JTO Clinical and Research Reports, 2021, 2, 100113
0.95Citations (PDF)
6Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
Npj Precision Oncology, 2021, 5,
6.543Citations (PDF)
7Mechanisms of resistance to osimertinib
Journal of Thoracic Disease, 2020, 12, 2851-2858
1.284Citations (PDF)
8Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
Journal of Thoracic Oncology, 2020, 15, 416-425
2.117Citations (PDF)
9Novel molecular targets for the treatment of lung cancer
Current Opinion in Oncology, 2020, 32, 37-43
2.123Citations (PDF)
10Proprotein convertase furin in SARS-CoV-2 and non-small cell lung cancer
Translational Lung Cancer Research, 2020, 9, 945-947
2.02Citations (PDF)
11SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer
Translational Lung Cancer Research, 2020, 9, 1810-1821
2.014Citations (PDF)
12SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations
IScience, 2020, 23, 101832
3.618Citations (PDF)
13Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries
Therapeutic Advances in Respiratory Disease, 2020, 14,
2.610Citations (PDF)
14Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma
JTO Clinical and Research Reports, 2020, 1, 100084
0.92Citations (PDF)
15Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
Expert Review of Respiratory Medicine, 2019, 13, 1019-1028
2.413Citations (PDF)
16<p>Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives</p>
OncoTargets and Therapy, 2019, Volume 12, 4567-4575
2.722Citations (PDF)
17Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions
Molecular Oncology, 2019, 13, 2633-2645
4.186Citations (PDF)
18Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma
Cell Communication and Signaling, 2019, 17,
7.928Citations (PDF)
19BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale
Cancers, 2019, 11, 1381
3.858Citations (PDF)
20Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines
Translational Lung Cancer Research, 2019, 8, 340-351
2.016Citations (PDF)
21Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)
Thoracic Cancer, 2019, 10, 508-518
2.010Citations (PDF)
22Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
Journal of Thoracic Oncology, 2019, 14, 1266-1276
2.1117Citations (PDF)
23Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP)
Frontiers in Oncology, 2019, 9,
2.626Citations (PDF)
24Cancer Stem Cell Biomarkers in EGFR-Mutation–Positive Non–Small-Cell Lung Cancer
Clinical Lung Cancer, 2019, 20, 167-177
2.848Citations (PDF)
25Targeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancer
Translational Lung Cancer Research, 2019, 8, 667-673
2.013Citations (PDF)
26Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
International Journal of Biological Sciences, 2019, 15, 2607-2614
8.530Citations (PDF)
27Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)
EBioMedicine, 2019, 39, 207-214
9.743Citations (PDF)
28Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins
Cancer Research, 2019, 79, 546-556
3.878Citations (PDF)
29EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
Translational Cancer Research, 2019, 8, S23-S47
1.297Citations (PDF)
30Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy
Melanoma Research, 2018, 28, 195-203
1.522Citations (PDF)
31Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
Therapeutic Advances in Medical Oncology, 2018, 10,
3.7111Citations (PDF)
32RNA Analysis as a Tool to Determine Clinically Relevant Gene Fusions and Splice Variants
Archives of Pathology and Laboratory Medicine, 2018, 142, 474-479
2.421Citations (PDF)
33Clinical assessment of immune-related adverse events
Therapeutic Advances in Medical Oncology, 2018, 10,
3.7128Citations (PDF)
34Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
EBioMedicine, 2018, 29, 112-127
9.776Citations (PDF)
35Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
Therapeutic Advances in Medical Oncology, 2018, 10,
3.7254Citations (PDF)
36Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
Therapeutic Advances in Medical Oncology, 2018, 10,
3.7118Citations (PDF)
37Liquid biopsy for lung cancer early detection
Journal of Thoracic Disease, 2018, 10, S882-S897
1.2117Citations (PDF)
38Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC
Translational Lung Cancer Research, 2018, 7, 691-702
2.011Citations (PDF)
39Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer
Translational Lung Cancer Research, 2018, 7, S165-S170
2.022Citations (PDF)
40Tumor mutational burden as predictive factor of response to immunotherapy
Translational Lung Cancer Research, 2018, 7, S358-S361
2.08Citations (PDF)
41Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?
Translational Lung Cancer Research, 2018, 7, S198-S201
2.013Citations (PDF)
42Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC
Translational Lung Cancer Research, 2018, 7, S183-S186
2.01Citations (PDF)
43ARID1A Gene Driver Mutations in Lung Adenocarcinomas
Journal of Thoracic Oncology, 2018, 13, e255-e257
2.130Citations (PDF)
44Activation of viral defense signaling in cancer
Therapeutic Advances in Medical Oncology, 2018, 10,
3.719Citations (PDF)
45Anti–Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells
Journal of Thoracic Oncology, 2018, 13, 1324-1337
2.134Citations (PDF)
46Therapeutic approaches for T790M mutation positive non-small-cell lung cancer
Expert Review of Anticancer Therapy, 2018, 18, 1021-1030
2.529Citations (PDF)
47The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring
Current Oncology Reports, 2018, 20,
4.264Citations (PDF)
48Response to crizotinib in a non-small-cell lung cancer patient harboring an <em>EML4-ALK</em> fusion with an atypical <em>LTBP1</em> insertion
OncoTargets and Therapy, 2018, Volume 11, 1117-1120
2.74Citations (PDF)
49Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
Lancet Respiratory Medicine,the, 2018, 6, 771-781
23.4198Citations (PDF)
50An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer
Expert Review of Molecular Diagnostics, 2018, 18, 35-45
3.042Citations (PDF)
51Pharmacological management of relapsed/refractory NSCLC with chemical drugs
Expert Opinion on Pharmacotherapy, 2017, 18, 295-304
2.112Citations (PDF)
52Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non–Small-Cell Lung Cancer Patients
Clinical Chemistry, 2017, 63, 751-760
1.166Citations (PDF)
53Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients
British Journal of Cancer, 2017, 116, 802-810
5.5141Citations (PDF)
54Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Lancet Respiratory Medicine,the, 2017, 5, 435-444
23.4179Citations (PDF)
55Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer
Expert Opinion on Investigational Drugs, 2017, 26, 713-722
3.919Citations (PDF)
56Second-line therapy of squamous non-small cell lung cancer: an evolving landscape
Expert Review of Respiratory Medicine, 2017, 11, 469-479
2.413Citations (PDF)
57Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP)
Targeted Oncology, 2017, 12, 513-523
3.225Citations (PDF)
58Using genetics to predict patient response to platinum-based chemotherapy
Expert Review of Precision Medicine and Drug Development, 2017, 2, 21-32
0.97Citations (PDF)
59Tracking MET de-addiction in lung cancer: A road towards the oncogenic target
Cancer Treatment Reviews, 2017, 60, 1-11
9.636Citations (PDF)
60Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets
Cancer Cell, 2017, 32, 238-252.e9
33.1311Citations (PDF)
61Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
Drug Design, Development and Therapy, 2017, Volume 11, 2047-2063
6.933Citations (PDF)
62Low RAP80 mRNA Expression Correlates with Shorter Survival in Sporadic High-Grade Serous Ovarian Carcinoma
International Journal of Biological Markers, 2017, 32, 90-95
1.91Citations (PDF)
63Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
Lung Cancer: Targets and Therapy, 2017, Volume 8, 109-125
2.567Citations (PDF)
64Possible application of circulating free tumor DNA in non-small cell lung cancer patients
Journal of Thoracic Disease, 2017, 9, S1364-S1372
1.214Citations (PDF)
65Osimertinib: a breakthrough for the treatment of epidermal growth factor receptor mutant lung adenocarcinoma
Translational Cancer Research, 2017, 6, S117-S121
1.21Citations (PDF)
66Human endogenous retroviruses and cancer
Cancer Biology and Medicine, 2016, 13, 483
5.198Citations (PDF)
67Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report
Translational Lung Cancer Research, 2016, 5, 532-537
2.05Citations (PDF)
68Annual or biennial lung cancer CT screening?
Journal of Thoracic Disease, 2016, 8, 2424-2426
1.24Citations (PDF)
69Unraveling the genomic complexity of small cell lung cancer
Translational Lung Cancer Research, 2016, 5, 363-366
2.035Citations (PDF)
70Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients
Translational Lung Cancer Research, 2016, 5, 525-531
2.023Citations (PDF)
71Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
OncoTargets and Therapy, 2016, Volume 9, 6361-6376
2.721Citations (PDF)
72Liquid Biopsy in Non-Small Cell Lung Cancer
Frontiers in Medicine, 2016, 3,
2.454Citations (PDF)
73Recent developments in the use of immunotherapy in non-small cell lung cancer
Expert Review of Respiratory Medicine, 2016, 10, 781-798
2.430Citations (PDF)
74Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma
Pulmonary Therapy, 2016, 2, 1-18
2.62Citations (PDF)
75SMARCA4 /BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non–Small Cell Lung Cancer
Clinical Cancer Research, 2016, 22, 2396-2404
6.8141Citations (PDF)
76Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?
Journal of Thoracic Oncology, 2016, 11, 453-474
2.1176Citations (PDF)
77Feasibility of Cell-Free Circulating Tumor DNA Testing for Lung Cancer
Biomarkers in Medicine, 2016, 10, 417-430
1.524Citations (PDF)
78HER3 as a Therapeutic Target in Cancer
BioDrugs, 2016, 31, 63-73
6.234Citations (PDF)
79Immune checkpoint blockade (ICB) for first line treatment in non-small cell lung cancer (NSCLC)
Translational Cancer Research, 2016, 5, S408-S410
1.23Citations (PDF)
80TIME for biomarker-driven immunotherapy in non-small-cell lung cancer patients
Translational Cancer Research, 2016, 5, 127-130
1.22Citations (PDF)
81BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
Scientific Reports, 2015, 5,
3.464Citations (PDF)
82BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors
Melanoma Research, 2015, 25, 486-495
1.578Citations (PDF)
83Targeting PD-1/PD-L1 in lung cancer: current perspectives
Lung Cancer: Targets and Therapy, 2015, , 55
2.511Citations (PDF)
84Non-small-cell lung cancer
Nature Reviews Disease Primers, 2015, 1,
47.21,005Citations (PDF)
85The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Nature Genetics, 2015, 47, 250-256
25.2522Citations (PDF)
86Association ofEGFRL858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial
JAMA Oncology, 2015, 1, 149
14.4236Citations (PDF)
87Relationship between gene mutation and lung cancer metastasis
Cancer and Metastasis Reviews, 2015, 34, 243-248
7.023Citations (PDF)
88Pharmacogenomics in the Treatment of Lung Cancer: an Update
Pharmacogenomics, 2015, 16, 1751-1760
1.56Citations (PDF)
89RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer
Nature Medicine, 2015, 21, 1038-1047
33.0283Citations (PDF)
90Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
Lung Cancer: Targets and Therapy, 2014, , 73
2.55Citations (PDF)
91Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
Expert Review of Anticancer Therapy, 2014, 14, 807-815
2.519Citations (PDF)
92The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
Clinical Cancer Research, 2014, 20, 2001-2010
6.8227Citations (PDF)
93Genetics and biomarkers in personalisation of lung cancer treatment
Lancet, The, 2013, 382, 720-731
62.4286Citations (PDF)
94KRAS Mutations in Lung Cancer
Clinical Lung Cancer, 2013, 14, 205-214
2.8220Citations (PDF)
95PharmGKB summary
Pharmacogenetics and Genomics, 2013, 23, 636-642
1.216Citations (PDF)
96BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non–Small-Cell Lung Cancer Patients with EGFR Mutations
Journal of Thoracic Oncology, 2013, 8, 295-300
2.117Citations (PDF)
97Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide
PLoS ONE, 2013, 8, e74611
2.332Citations (PDF)
98Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group
Lung Cancer, 2012, 77, 146-150
2.637Citations (PDF)
99Second-line Paclitaxel/Carboplatin Versus Vinorelbine/Carboplatin in Patients Who Have Advanced Non–Small-Cell Lung Cancer Pretreated With Non–Platinum-Based Chemotherapy: A Multicenter Randomized Phase II Study
Clinical Lung Cancer, 2011, 12, 100-105
2.86Citations (PDF)
100Unmet Medical Needs in Non-Small-Cell Lung Cancer Treatment: How to Design Pre-Emptive Combination Therapies
European Medical Journal Oncology, 0, , 48-53
0.00Citations (PDF)